GlassScriptPhysician profile
Jodi D Pukl
NPI 1962490540
$1,499.26
in general payments reported to CMS, 2019-2025
15 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $27.47 · 2021: $46.99 · 2022: $97.25 · 2023: $325 · 2024: $177 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $721.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $720.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $288.33 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Tarsus Pharmaceuticals, INC. | $168.30 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $161.83 | 2021-2024 | Eysuvis, Total30 |
| Aerie Pharmaceuticals, INC. | $135.52 | 2019 | |
| Abbvie INC. | $112.64 | 2022-2023 | |
| Sight Sciences, INC. | $99.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $97.88 | 2019 | |
| Allergan, INC. | $89.75 | 2019 | |
| Abb Con-Cise Optical Group LLC | $89.42 | 2022-2025 | Contact Lens, Spectacle Lenses |
| Bausch & Lomb Americas INC. | $65.66 | 2023-2024 | Infuse |
| Johnson & Johnson Vision Care, INC. | $64.99 | 2020-2025 | |
| Visioneering Technologies, INC. | $63.80 | 2019 | |
| Optovue, INC. | $24.60 | 2021 | |
| Dompe US, INC. | $21.51 | 2024 | Oxervate |
| Spark Therapeutics, INC. | $15.47 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Pukl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.